Emerging role of BAD and DAD1 as potential targets and biomarkers in cancer (Review)
- Authors:
- Yulou Luo
- You Wu
- Hai Huang
- Na Yi
- Yan Chen
-
Affiliations: First Clinical Medical College, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830054, P.R. China, Nursing College, Binzhou Medical University, Binzhou, Shandong 264003, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Autonomous Region 830017, P.R. China - Published online on: September 28, 2021 https://doi.org/10.3892/ol.2021.13072
- Article Number: 811
-
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
El Bali M, Bakkach J and Mechita MB: Colorectal cancer: From genetic landscape to targeted therapy. J Oncol. 2021:99181162021. View Article : Google Scholar : PubMed/NCBI |
|
|
Fan J, Shen X, Wang Y, Zhou HL, Liu G, Li YL and Xu ZX: Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomed Pharmacother. 130:1106212020. View Article : Google Scholar : PubMed/NCBI |
|
|
Huang M, Shen A, Ding J and Geng M: Molecularly targeted cancer therapy: Some lessons from the past decade. Trends Pharmacol Sci. 35:41–50. 2014. View Article : Google Scholar : PubMed/NCBI |
|
|
Troxell ML, Higgins JP and Kambham N: Antineoplastic treatment and renal injury: An update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 23:310–329. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Sun M, Wang T, Li L, Li X, Zhai Y, Zhang J and Li W: The application of inorganic nanoparticles in molecular targeted cancer therapy: EGFR targeting. Front Pharmacol. 12:7024452021. View Article : Google Scholar : PubMed/NCBI |
|
|
Eisenberg-Lerner A, Bialik S, Simon HU and Kimchi A: Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 16:966–975. 2009. View Article : Google Scholar : PubMed/NCBI |
|
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI |
|
|
Blandino G and Strano S: BCL-2: The pendulum of the cell fate. J Exp Clin Cancer Res. 16:3–10. 1997.PubMed/NCBI |
|
|
Sastry KS, Al-Muftah MA, Li P, Al-Kowari MK, Wang E, Chouchane AI, Kizhakayil D, Kulik G, Marincola FM, Haoudi A and Chouchane L: Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ. 21:1936–1949. 2014. View Article : Google Scholar : PubMed/NCBI |
|
|
Sanjay A, Fu J and Kreibich G: DAD1 is required for the function and the structural integrity of the oligosaccharyltransferase complex. J Biol Chem. 273:26094–26099. 1998. View Article : Google Scholar : PubMed/NCBI |
|
|
Nakashima T, Sekiguchi T, Kuraoka A, Fukushima K, Shibata Y, Komiyama S and Nishimoto T: Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells. Mol Cell Biol. 13:6367–6374. 1993. View Article : Google Scholar : PubMed/NCBI |
|
|
Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI |
|
|
Bhola PD and Letai A: Mitochondria-judges and executioners of cell death sentences. Mol Cell. 61:695–704. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Hsu SY, Kaipia A, Zhu L and Hsueh AJ: Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol Endocrinol. 11:1858–1867. 1997. View Article : Google Scholar : PubMed/NCBI |
|
|
Danial NN: BAD: Undertaker by night, candyman by day. Oncogene. 27 (Suppl 1):S53–S70. 2008. View Article : Google Scholar : PubMed/NCBI |
|
|
Polzien L, Baljuls A, Rennefahrt UEE, Fischer A, Schmitz W, Zahedi RP, Sickmann A, Metz R, Albert S, Benz R, et al: Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: Pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem. 284:28004–28020. 2009. View Article : Google Scholar : PubMed/NCBI |
|
|
Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80:285–291. 1995. View Article : Google Scholar : PubMed/NCBI |
|
|
del Peso L, González-García M, Page C, Herrera R and Nuñez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:687–689. 1997. View Article : Google Scholar : PubMed/NCBI |
|
|
Tan Y, Demeter MR, Ruan H and Comb MJ: BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem. 275:25865–25869. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Lizcano JM, Morrice N and Cohen P: Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J. 349:547–557. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhou XM, Liu Y, Payne G, Lutz RJ and Chittenden T: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem. 275:25046–25051. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Radisavljevic Z: AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol. 228:21–24. 2013. View Article : Google Scholar : PubMed/NCBI |
|
|
Yan J, Xiang J, Lin Y, Ma J, Zhang J, Zhang H, Sun J, Danial NN, Liu J and Lin A: Inactivation of BAD by IKK inhibits TNFα-induced apoptosis independently of NF-κB activation. Cell. 152:304–315. 2013. View Article : Google Scholar : PubMed/NCBI |
|
|
Pandey V, Wang B, Mohan CD, Raquib AR, Rangappa S, Srinivasa V, Fuchs JE, Girish KS, Zhu T, Bender A, et al: Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation. Proc Natl Acad Sci USA. 115:E10505–E10514. 2018. View Article : Google Scholar : PubMed/NCBI |
|
|
Yang H, Masters SC, Wang H and Fu H: The proapoptotic protein Bad binds the amphipathic groove of 14-3-3zeta. Biochim Biophys Acta. 1547:313–319. 2001. View Article : Google Scholar : PubMed/NCBI |
|
|
Hekman M, Albert S, Galmiche A, Rennefahrt UEE, Fueller J, Fischer A, Puehringer D, Wiese S and Rapp UR: Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding. J Biol Chem. 281:17321–17336. 2006. View Article : Google Scholar : PubMed/NCBI |
|
|
Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ, Andrews D, Knudson CM and Yang E: Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 22:5459–5470. 2003. View Article : Google Scholar : PubMed/NCBI |
|
|
Linette GP, Li Y, Roth K and Korsmeyer SJ: Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA. 93:9545–9552. 1996. View Article : Google Scholar : PubMed/NCBI |
|
|
Chattopadhyay A, Chiang CW and Yang E: BAD/BCL-[X(L)] heterodimerization leads to bypass of G0/G1 arrest. Oncogene. 20:4507–4518. 2001. View Article : Google Scholar : PubMed/NCBI |
|
|
Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, et al: Functional and physical interaction between Bcl-X(L) and a BH3-like domain in beclin-1. EMBO J. 26:2527–2539. 2007. View Article : Google Scholar : PubMed/NCBI |
|
|
Ranger AM, Zha J, Harada H, Datta SR, Danial NN, Gilmore AP, Kutok JL, Le Beau MM, Greenberg ME and Korsmeyer SJ: Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 100:9324–9329. 2003. View Article : Google Scholar : PubMed/NCBI |
|
|
Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ and Greenberg ME: Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 3:631–643. 2002. View Article : Google Scholar : PubMed/NCBI |
|
|
Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, et al: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 424:952–956. 2003. View Article : Google Scholar : PubMed/NCBI |
|
|
Githaka JM, Tripathi N, Kirschenman R, Patel N, Pandya V, Kramer DA, Montpetit R, Zhu LF, Sonenberg N, Fahlman RP, et al: BAD regulates mammary gland morphogenesis by 4E-BP1-mediated control of localized translation in mouse and human models. Nat Commun. 12:29392021. View Article : Google Scholar : PubMed/NCBI |
|
|
Giménez-Cassina A, Garcia-Haro L, Choi CS, Osundiji MA, Lane EA, Huang H, Yildirim MA, Szlyk B, Fisher JK, Polak K, et al: Regulation of hepatic energy metabolism and gluconeogenesis by BAD. Cell Metab. 19:272–284. 2014. View Article : Google Scholar : PubMed/NCBI |
|
|
National Center for Biotechnology Information (NCBI), . BAD BCL2 associated agonist of cell death [Homo sapiens (human)]. NCBI; Bethesda MD: 2021, http://www.ncbi.nlm.nih.gov/gene/572September 2–2021 |
|
|
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI |
|
|
Sastry KS, Karpova Y and Kulik G: Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem. 281:27367–27377. 2006. View Article : Google Scholar : PubMed/NCBI |
|
|
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J and Rosen N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 8:287–297. 2005. View Article : Google Scholar : PubMed/NCBI |
|
|
Polzien L, Baljuls A, Albrecht M, Hekman M and Rapp UR: BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling. J Biol Chem. 286:17934–17944. 2011. View Article : Google Scholar : PubMed/NCBI |
|
|
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 363:1117–1127. 2010. View Article : Google Scholar : PubMed/NCBI |
|
|
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI |
|
|
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI |
|
|
Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A and Wood KC: RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 7:ra1222014. View Article : Google Scholar : PubMed/NCBI |
|
|
Huang N, Zhu J, Liu D, Li YL, Chen BJ, He YQ, Liu K, Mo XM and Li WM: Overexpression of Bcl-2-associated death inhibits A549 cell growth in vitro and in vivo. Cancer Biother Radiopharm. 27:164–168. 2012. View Article : Google Scholar : PubMed/NCBI |
|
|
Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M and Kulik G: Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One. 4:e62242009. View Article : Google Scholar : PubMed/NCBI |
|
|
Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Zgheib NB, Boac BM, Orr BC, Judson PL, et al: BAD-mediated apoptotic pathway is associated with human cancer development. Int J Mol Med. 35:1081–1087. 2015. View Article : Google Scholar : PubMed/NCBI |
|
|
Kulik G: ADRB2-Targeting therapies for prostate cancer. Cancers (Basel). 11:3582019. View Article : Google Scholar : PubMed/NCBI |
|
|
Mann J, Githaka JM, Buckland TW, Yang N, Montpetit R, Patel N, Li L, Baksh S, Godbout R, Lemieux H and Goping IS: Non-canonical BAD activity regulates breast cancer cell and tumor growth via 14-3-3 binding and mitochondrial metabolism. Oncogene. 38:3325–3339. 2019. View Article : Google Scholar : PubMed/NCBI |
|
|
Lu P, Bowman KE, Brown SM, Joklik-Mcleod M, Mause ER, Nguyen HTN and Lim CS: p53-bad: A novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy. Mol Pharm. 16:3386–3398. 2019. View Article : Google Scholar : PubMed/NCBI |
|
|
Hu W, Fu J, Lu SX, Liu LL, Luo RZ, Yun JP and Zhang CZ: Decrease of Bcl-xL/Bcl-2-associated death promoter in hepatocellular carcinoma indicates poor prognosis. Am J Cancer Res. 5:1805–1813. 2015.PubMed/NCBI |
|
|
Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, et al: BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion. Exp Cell Res. 331:1–10. 2015. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhu X, Yu Y, Hou X, Xu J, Tan Z, Nie X, Ling Z and Ge M: Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. Oncol Lett. 15:1149–1156. 2018.PubMed/NCBI |
|
|
Yu Y, Zhong Z and Guan Y: The downregulation of Bcl-xL/Bcl-2-associated death promoter indicates worse outcomes in patients with small cell lung carcinoma. Int J Clin Exp Pathol. 8:13075–13082. 2015.PubMed/NCBI |
|
|
Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, Han M, Saeed-Vafa D, Soliman H, Henry B, et al: Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep. 9:174962019. View Article : Google Scholar : PubMed/NCBI |
|
|
Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, et al: The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 124:119–124. 2012. View Article : Google Scholar : PubMed/NCBI |
|
|
Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 60:5988–5994. 2000.PubMed/NCBI |
|
|
Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, et al: BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 17:6356–6366. 2011. View Article : Google Scholar : PubMed/NCBI |
|
|
Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, et al: BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 23:35–42. 2012. View Article : Google Scholar : PubMed/NCBI |
|
|
Yu B, Sun X, Shen HY, Gao F, Fan YM and Sun ZJ: Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res. 29:1072010. View Article : Google Scholar : PubMed/NCBI |
|
|
Mann J, Yang N, Montpetit R, Kirschenman R, Lemieux H and Goping IS: BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis. Sci Rep. 10:3552020. View Article : Google Scholar : PubMed/NCBI |
|
|
Yu N, Seedhouse C, Russell N and Pallis M: Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737. Leuk Lymphoma. 59:2447–2453. 2018. View Article : Google Scholar : PubMed/NCBI |
|
|
Yiau SK, Lee C, Tohit ER, Chang KM and Abdullah M: Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia. J Recept Signal Transduct Res. 39:276–282. 2019. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhou Y, Sun K, Ma Y, Yang H, Zhang Y, Kong X and Wei L: Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells. Sci Rep. 4:53822014. View Article : Google Scholar : PubMed/NCBI |
|
|
Kim H, Choi H and Lee SK: Epstein-barr virus microRNA miR-BART20-5p suppresses lytic induction by inhibiting BAD-mediated caspase-3-dependent apoptosis. J Virol. 90:1359–1368. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, Liu J, Yu S and He S: Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: Suppression by carnosic acid nanoparticle. Int J Nanomedicine. 11:6401–6420. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhao X, Fan Y, Lu C, Li H, Zhou N, Sun G and Fan H: PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion. Bosn J Basic Med Sci. 19:274–281. 2019.PubMed/NCBI |
|
|
Liu Z, Zhang G, Huang S, Cheng J, Deng T, Lu X, Adeshakin FO, Chen Q and Wan X: Induction of apoptosis in hematological cancer cells by dorsomorphin correlates with BAD upregulation. Biochem Biophys Res Commun. 522:704–708. 2020. View Article : Google Scholar : PubMed/NCBI |
|
|
Mansouri RA and Percival SS: Cranberry extract initiates intrinsic apoptosis in HL-60 cells by increasing BAD activity through inhibition of AKT phosphorylation. BMC Complement Med Ther. 20:712020. View Article : Google Scholar : PubMed/NCBI |
|
|
Endo H, Inoue I, Masunaka K, Tanaka M and Yano M: Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad. Biosci Biotechnol Biochem. 84:2440–2447. 2020. View Article : Google Scholar : PubMed/NCBI |
|
|
Gao YP, Li L, Yan J, Hou XX, Jia YX, Chang ZW, Guan XY and Qin YR: Down-regulation of CIDEA promoted tumor growth and contributed to cisplatin resistance by regulating the JNK-p21/bad signaling pathways in esophageal squamous cell carcinoma. Front Oncol. 10:6278452020. View Article : Google Scholar : PubMed/NCBI |
|
|
Kelleher DJ and Gilmore R: DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. Proc Natl Acad Sci USA. 94:4994–4999. 1997. View Article : Google Scholar : PubMed/NCBI |
|
|
Roboti P and High S: The oligosaccharyltransferase subunits OST48, DAD1 and KCP2 function as ubiquitous and selective modulators of mammalian N-glycosylation. J Cell Sci. 125:3474–3484. 2012.PubMed/NCBI |
|
|
Apte SS, Mattei MG, Seldin MF and Olsen BR: The highly conserved defender against the death 1 (DAD1) gene maps to human chromosome 14q11-q12 and mouse chromosome 14 and has plant and nematode homologs. FEBS Lett. 363:304–306. 1995. View Article : Google Scholar : PubMed/NCBI |
|
|
National Center for Biotechnology Information (NCBI), . DAD1, defender against cell death 1 [Homo sapiens (human)]. Gene ID: 1603. NCBI; Bethesda MD: 2021, http://www.ncbi.nlm.nih.gov/gene/1603September 3–2021 |
|
|
Zhang Y, Cui C and Lai ZC: The defender against apoptotic cell death 1 gene is required for tissue growth and efficient N-glycosylation in Drosophila melanogaster. Dev Biol. 420:186–195. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Makishima T, Nakashima T, Nagata-Kuno K, Fukushima K, Iida H, Sakaguchi M, Ikehara Y, Komiyama S and Nishimoto T: The highly conserved DAD1 protein involved in apoptosis is required for N-linked glycosylation. Genes Cells. 2:129–141. 1997. View Article : Google Scholar : PubMed/NCBI |
|
|
Brewster JL, Martin SL, Toms J, Goss D, Wang K, Zachrone K, Davis A, Carlson G, Hood L and Coffin JD: Deletion of Dad1 in mice induces an apoptosis-associated embryonic death. Genesis. 26:271–278. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Hong NA, Flannery M, Hsieh SN, Cado D, Pedersen R and Winoto A: Mice lacking Dad1, the defender against apoptotic death-1, express abnormal N-linked glycoproteins and undergo increased embryonic apoptosis. Dev Biol. 220:76–84. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Hong NA, Kabra NH, Hsieh SN, Cado D and Winoto A: In vivo overexpression of Dad1, the defender against apoptotic death-1, enhances T cell proliferation but does not protect against apoptosis. J Immunol. 163:1888–1893. 1999.PubMed/NCBI |
|
|
Moharikar S, D'Souza JS and Rao BJ: A homologue of the defender against the apoptotic death gene (dad1) in UV-exposed Chlamydomonas cells is downregulated with the onset of programmed cell death. J Biosci. 32:261–270. 2007. View Article : Google Scholar : PubMed/NCBI |
|
|
Mittapalli O and Shukle RH: Molecular characterization and responsive expression of a defender against apoptotic cell death homologue from the Hessian fly, Mayetiola destructor. Comp Biochem Physiol B Biochem Mol Biol. 149:517–523. 2008. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhu L, Song L, Zhang H, Zhao J, Li C and Xu W: Molecular cloning and responsive expression to injury stimulus of a defender against cell death 1 (DAD1) gene from bay scallops Argopecten irradians. Mol Biol Rep. 35:125–132. 2008. View Article : Google Scholar : PubMed/NCBI |
|
|
Wang MQ, Wang BJ, Liu M, Jiang KY and Wang L: Molecular characterization of a defender against apoptotic cell death 1 gene (CfDAD1) from the mollusk Chlamys farreri. Invertebr Surviv J. 15:294–301. 2018. |
|
|
Makishima T, Yoshimi M, Komiyama S, Hara N and Nishimoto T: A subunit of the mammalian oligosaccharyltransferase, DAD1, interacts with Mcl-1, one of the bcl-2 protein family. J Biochem. 128:399–405. 2000. View Article : Google Scholar : PubMed/NCBI |
|
|
Paunel-Görgülü A, Kirichevska T, Lögters T, Windolf J and Flohé S: Molecular mechanisms underlying delayed apoptosis in neutrophils from multiple trauma patients with and without sepsis. Mol Med. 18:325–335. 2012. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhao H, Li Z, Zhu Y, Bian S, Zhang Y, Qin L, Naik AK, He J, Zhang Z, Krangel MS and Hao B: A role of the CTCF binding site at enhancer Eα in the dynamic chromatin organization of the Tcra-Tcrd locus. Nucleic Acids Res. 48:9621–9636. 2020. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhang Y, Yu M, Dong J, Wu Y and Tian W: Identification of novel Adipokines through proteomic profiling of small extracellular vesicles derived from adipose tissue. J Proteome Res. 19:3130–3142. 2020. View Article : Google Scholar : PubMed/NCBI |
|
|
Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, et al: Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. Biochim Biophys Acta. 1536:1–12. 2001. View Article : Google Scholar : PubMed/NCBI |
|
|
Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, Cordeu L, Andion E, Escalada A, Zarate R, Salgado E, et al: Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma. Oncol Rep. 12:287–292. 2004.PubMed/NCBI |
|
|
Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN and Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer. 47:591–603. 2008. View Article : Google Scholar : PubMed/NCBI |
|
|
Wilson BJ: Meta-analysis of SUMO1. BMC Res Notes. 1:602008. View Article : Google Scholar : PubMed/NCBI |
|
|
Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, et al: Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis. 32:1216–1222. 2011. View Article : Google Scholar : PubMed/NCBI |
|
|
Zhu Y, Xu H, Chen H, Xie J, Shi M, Shen B, Deng X, Liu C, Zhan X and Peng C: Proteomic analysis of solid pseudopapillary tumor of the pancreas reveals dysfunction of the endoplasmic reticulum protein processing pathway. Mol Cell Proteomics. 13:2593–2603. 2014. View Article : Google Scholar : PubMed/NCBI |
|
|
Schnormeier AK, Pommerenke C, Kaufmann M, Drexler HG and Koeppel M: Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia. Sci Rep. 10:97752020. View Article : Google Scholar : PubMed/NCBI |
|
|
Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC and Rowley D: Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 64:6082–6090. 2004. View Article : Google Scholar : PubMed/NCBI |
|
|
True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, et al: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA. 103:10991–10996. 2006. View Article : Google Scholar : PubMed/NCBI |
|
|
Wang M, Xiao X, Zeng F, Xie F, Fan Y, Huang C, Jiang G and Wang L: Common and differentially expressed long noncoding RNAs for the characterization of high and low grade bladder cancer. Gene. 592:78–85. 2016. View Article : Google Scholar : PubMed/NCBI |
|
|
Yoon J, Kim ES, Lee SJ, Park CW, Cha HJ, Hong BH and Choi KY: Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. J Gynecol Oncol. 21:255–261. 2010. View Article : Google Scholar : PubMed/NCBI |
|
|
Bhasin N: DAD1 as potential therapeutic target and biomarker in prostate cancer (unpublished PhD thesis). Tulane University; 2015 |
|
|
Al-Bazz YO, Underwood JC, Brown BL and Dobson PR: Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer. 45:694–704. 2009. View Article : Google Scholar : PubMed/NCBI |
|
|
Fernando R, Foster JS, Bible A, Ström A, Pestell RG, Rao M, Saxton A, Baek SJ, Yamaguchi K, Donnell R, et al: Breast cancer cell proliferation is inhibited by BAD: Regulation of cyclin D1. J Biol Chem. 282:28864–28873. 2007. View Article : Google Scholar : PubMed/NCBI |
|
|
Meiliwuerti D: The regulation mechanism study of Bad on Dad1 gene in esophageal squamous cells. MaD ThesisXinjiang Medical University, China2017.(In Chinese). |
|
|
Cell Signaling Technology (CST), . Mitochondrial control of apoptosis. CST; Danvers, MA: 2021, https://www.cellsignal.com/learn-and-support/order-support?countryId=10036#collapse00July 1–2021 |
|
|
Cell Signaling Technology (CST), . Regulation of apoptosis. CST; Danvers, MA: 2021, http://www.cellsignal.com/pathways/regulation-of-apoptosis-pathwayJuly 1–2021 |
|
|
Cell Signaling Technology (CST), . Inhibition of apoptosis. CST; Danvers, MA: 2021, http://www.cellsignal.com/pathways/inhibition-of-apoptosis-pathwayJuly 1–2021 |
|
|
Bui NL, Pandey V, Zhu T, Ma L, Basappa and Lobie PE: Bad phosphorylation as a target of inhibition in oncology. Cancer Lett. 415:177–186. 2018. View Article : Google Scholar : PubMed/NCBI |
